HONG KONG – Invossa-K, a first-in-class cell and gene therapy that made headlines in 2017 when South Korean regulators cleared its use to treat osteoarthritis of the knee, is now on the verge of being phased out of the domestic market at least for one year and possibly for good, after being hit by a scandal involving its component ingredients.